New York, NY -- (SBWIRE) -- 01/09/2014 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Acasti Pharma Inc (NASDAQ:ACST), China New Borun Corp (NYSE:BORN), IMRIS Inc (NASDAQ:IMRS), Ion Geophysical Corp (NYSE:IO)
Acasti Pharma Inc (NASDAQ:ACST) showed a volume of 1.96 million shares by the end of last trade whereas the average volume of the stock remained 369,073.00 shares. The stock opened the session at $1.29 but then moved to $1.40. At that price, the stock showed a positive performance of 9.38%. Acasti Pharma Inc. (Acasti) is engaged in developing a product portfolio of long-chain omega-3 phospholipids. Acasti is a majority owned subsidiary of Neptune Technologies and Bioressources Inc. (Neptune). The Company has one operating segment: the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. The Company’s product portfolio includes concentrated phospholipids which functionalize eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Acasti is the producer of anti-dyslipidemic prescription drugs (CaPre),
Will ACST Continue To Move Higher? Find Out Here
China New Borun Corp (NYSE:BORN) opened the session at $2.66 and closed the session at $3.12. The stock showed a positive performance of 18.18% in previous trading session. Traded with volume of 1.96 million shares in the prior session and the average volume of the stock remained 565,012.00 shares. China New Borun Corporation (New Borun) is a producer and distributor of corn-based edible alcohol in the People's Republic of China based on tons of edible alcohol produced. The Company’s edible alcohol products are primarily sold as an ingredient to producers of baijiu, who further blend the Company’s products into finished products sold under various brand names throughout China. Baijiu is a grain-based alcoholic beverage made from corn, wheat or barley, clear in color, with alcohol content ranging from 18% to 68%.
For How Long BORN will fight for Profitability? Read This Trend Analysis report
IMRIS Inc (NASDAQ:IMRS) opened the session at $1.52 and closed the session at $2.19. The stock showed a positive performance of 40.38% in previous trading session. Traded with volume of 1.96 million shares in the prior session and the average volume of the stock remained 118,555.00 shares. The beta of the stock remained 1.25. IMRIS Inc. (IMRIS) designs, manufactures and markets the VISIUS Surgical Theatre, a multifunctional surgical environment that provides intraoperative vision to clinicians. Designed to enable hospital’s clinical application needs, the VISIUS Surgical Theatre can incorporate magnetic resonance (MR) imaging, computed tomography (CT) imaging and x-ray angiography in a number of configurations to provide intraoperative images of diagnostic quality. IMRIS sells the VISIUS Surgical Theatres globally to hospitals that deliver clinical services to patients in the neurosurgical, cerebrovascular and cardiovascular markets.
Why Should Investors Buy IMRS After The Recent Gain? Just Go Here and Find Out
Ion Geophysical Corp (NYSE:IO) the stock decreased -4.29% and finished the session at $3.12. Traded with volume of 1.94 million shares in the prior session and the average volume of the stock remained 1.58 million shares. The beta of the stock remained 3.75. ION Geophysical Corporation (ION) is a technology-focused seismic solutions company, which provides acquisition equipment, software and planning and seismic processing services to the global energy industry. ION operates in four business segments: solutions, systems, software and INOVA Geophysical. The Company’s products and services include seismic data processing and reservoir imaging services; seismic data libraries; planning services for survey design and optimization; marine seismic data acquisition equipment; navigation,
Will IO Get Buyers Even After The Recent Rally? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)